PMID- 27636207
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20180918
IS  - 2159-9777 (Electronic)
IS  - 0279-1072 (Linking)
VI  - 48
IP  - 5
DP  - 2016 Nov-Dec
TI  - A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 
      3,4-Methylenedioxymethamphetamine (MDMA) Toxicity with Possible Metabolic 
      Interaction.
PG  - 351-354
AB  - We present a case of "ecstasy" ingestion revealing 
      3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dimethoxyamphetamine (3,4-DMA) 
      and absence of cytochrome P450 (CYP)-2D6 MDMA metabolites. CASE REPORT: A 
      19-year-old presented following a seizure. Initial vital signs were normal. 
      Laboratories were normal with the exception of sodium 127 mEq/L and urine drugs 
      of abuse screen positive for amphetamines. Twelve hours later, serum sodium was 
      114 mEq/L and a second seizure occurred. After receiving hypertonic saline (3%), 
      the patient had improvement in mental status and admitted to taking "ecstasy" at 
      a rave prior to her initial presentation. Liquid chromatography-time-of-flight 
      mass spectrometry (LC-TOF/MS) of serum and urine revealed MDMA, 3,4-DMA, and the 
      CYP-2B6 MDMA metabolites 3,4-methylendioxyamphetamine (MDA) and 
      4-hydroxy-3-methoxyamphetamine (HMA). The CYP2D6 metabolites of MDMA, 
      3,4-dihydromethamphetamine (HHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA), 
      were detected at very low levels. CONCLUSION: This case highlights the 
      polypharmacy which may exist among users of psychoactive illicit substances and 
      demonstrates that concurrent use of MDMA and 3,4-DMA may predispose patients to 
      severe toxicity. Toxicologists and other healthcare providers should be aware of 
      this potential toxicity.
FAU - Darracq, Michael A
AU  - Darracq MA
AD  - a Assistant Professor, Fresno Medical Education Program, Department of Emergency 
      Medicine, Division of Medical Toxicology , University of California San Francisco 
      , Fresno , CA , USA.
FAU - Thornton, Stephen L
AU  - Thornton SL
AD  - b Assistant Professor, Department of Emergency Medicine, Kansas Poison Control 
      System , University of Kansas Medical Center , Kansas City , KS , USA.
FAU - Minns, Alicia B
AU  - Minns AB
AD  - c Assistant Professor, Department of Emergency Medicine, Division of Toxicology , 
      University of California San Diego , San Diego , CA , USA.
FAU - Gerona, Roy R
AU  - Gerona RR
AD  - d Assistant Professor, Department of Laboratory Medicine , University of 
      California San Francisco , San Francisco , CA , USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160916
PL  - United States
TA  - J Psychoactive Drugs
JT  - Journal of psychoactive drugs
JID - 8113536
RN  - 0 (Amphetamines)
RN  - 0 (Hallucinogens)
RN  - 117652-28-5 (4-hydroxy-3-methoxymethamphetamine)
RN  - 120-26-3 (3,4-dimethoxyamphetamine)
RN  - 13026-44-3 (3-O-methyl-alpha-methyldopamine)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/metabolism
MH  - Amphetamines/administration & dosage/pharmacokinetics/*toxicity
MH  - Chromatography, Liquid/methods
MH  - Dopamine/analogs & derivatives/metabolism
MH  - Drug Interactions
MH  - Female
MH  - Hallucinogens/administration & dosage/pharmacokinetics/*toxicity
MH  - Humans
MH  - Mass Spectrometry/methods
MH  - Methamphetamine/analogs & derivatives/metabolism
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & 
      dosage/pharmacokinetics/*toxicity
MH  - Seizures/*chemically induced
MH  - Substance Abuse Detection/methods
MH  - Young Adult
OTO - NOTNLM
OT  - 3,4 dimethoxyamphetamine (DMA)
OT  - 3,4-methylenedioxymethamphetamine
OT  - liquid chromatography-time-of-flight mass spectrometry (LC-TOF/MS)
OT  - pharmacokinetics
EDAT- 2016/09/17 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/09/17 06:00
PHST- 2016/09/17 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/09/17 06:00 [entrez]
AID - 10.1080/02791072.2016.1225324 [doi]
PST - ppublish
SO  - J Psychoactive Drugs. 2016 Nov-Dec;48(5):351-354. doi: 
      10.1080/02791072.2016.1225324. Epub 2016 Sep 16.